Shanghai Pharmaceuticals Holding Co Ltd (601607) - Total Assets
Based on the latest financial reports, Shanghai Pharmaceuticals Holding Co Ltd (601607) holds total assets worth CN¥233.15 Billion CNY as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shanghai Pharmaceuticals Holding Co Ltd - Total Assets Trend (1994–2025)
This chart illustrates how Shanghai Pharmaceuticals Holding Co Ltd's total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shanghai Pharmaceuticals Holding Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Shanghai Pharmaceuticals Holding Co Ltd's total assets of CN¥233.15 Billion consist of 77.4% current assets and 22.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 14.0% |
| Accounts Receivable | CN¥82.31 Billion | 35.3% |
| Inventory | CN¥45.36 Billion | 19.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥8.85 Billion | 3.8% |
| Goodwill | CN¥12.67 Billion | 5.4% |
Asset Composition Trend (1994–2025)
This chart illustrates how Shanghai Pharmaceuticals Holding Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Pharmaceuticals Holding Co Ltd's current assets represent 77.4% of total assets in 2025, an increase from 44.8% in 1994.
- Cash Position: Cash and equivalents constituted 14.0% of total assets in 2025, up from 0.0% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 0.0% in 1994.
- Asset Diversification: The largest asset category is accounts receivable at 35.3% of total assets.
Shanghai Pharmaceuticals Holding Co Ltd Competitors by Total Assets
Key competitors of Shanghai Pharmaceuticals Holding Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
C.Q. Pharmaceutical Holding Co Ltd
SHE:000950
|
China | CN¥67.71 Billion |
|
Shenzhen Glory Medical Co Ltd
SHE:002551
|
China | CN¥3.56 Billion |
|
Shandong Realcan Pharmaceutical Co Ltd
SHE:002589
|
China | CN¥15.33 Billion |
|
Hanmi Science
KO:008930
|
Korea | ₩1.49 Trillion |
|
BCM Alliance Bhd
KLSE:0187
|
Malaysia | RM147.86 Million |
|
China National Accord Medicines Corp Ltd
SHE:200028
|
China | HK$50.56 Billion |
|
Qingdao Baheal Medical INC.
SHE:301015
|
China | CN¥7.59 Billion |
|
Excelsior Medical Co Ltd
TW:4104
|
Taiwan | NT$18.80 Billion |
Shanghai Pharmaceuticals Holding Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.33 | 1.36 | 1.22 |
| Quick Ratio | 1.00 | 1.05 | 0.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥45.27 Billion | CN¥45.78 Billion | CN¥20.44 Billion |
Shanghai Pharmaceuticals Holding Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shanghai Pharmaceuticals Holding Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.85 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 5.4% |
| Total Assets | CN¥233.15 Billion |
| Market Capitalization | $6.93 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Pharmaceuticals Holding Co Ltd's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Shanghai Pharmaceuticals Holding Co Ltd's assets grew by 5.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Shanghai Pharmaceuticals Holding Co Ltd (1994–2025)
The table below shows the annual total assets of Shanghai Pharmaceuticals Holding Co Ltd from 1994 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥233.15 Billion | +5.40% |
| 2024-12-31 | CN¥221.21 Billion | +4.36% |
| 2023-12-31 | CN¥211.97 Billion | +6.98% |
| 2022-12-31 | CN¥198.13 Billion | +21.23% |
| 2021-12-31 | CN¥163.44 Billion | +9.55% |
| 2020-12-31 | CN¥149.19 Billion | +8.87% |
| 2019-12-31 | CN¥137.03 Billion | +8.00% |
| 2018-12-31 | CN¥126.88 Billion | +34.49% |
| 2017-12-31 | CN¥94.34 Billion | +14.02% |
| 2016-12-31 | CN¥82.74 Billion | +11.30% |
| 2015-12-31 | CN¥74.34 Billion | +15.55% |
| 2014-12-31 | CN¥64.34 Billion | +14.26% |
| 2013-12-31 | CN¥56.31 Billion | +10.27% |
| 2012-12-31 | CN¥51.07 Billion | +7.14% |
| 2011-12-31 | CN¥47.67 Billion | +69.22% |
| 2010-12-31 | CN¥28.17 Billion | +225.39% |
| 2009-12-31 | CN¥8.66 Billion | +11.62% |
| 2008-12-31 | CN¥7.76 Billion | +8.84% |
| 2007-12-31 | CN¥7.13 Billion | +6.69% |
| 2006-12-31 | CN¥6.68 Billion | +4.74% |
| 2005-12-31 | CN¥6.38 Billion | -1.36% |
| 2004-12-31 | CN¥6.46 Billion | +5.03% |
| 2003-12-31 | CN¥6.15 Billion | +13.92% |
| 2002-12-31 | CN¥5.40 Billion | +25.85% |
| 2001-12-31 | CN¥4.29 Billion | +21.44% |
| 2000-12-31 | CN¥3.54 Billion | +15.70% |
| 1999-12-31 | CN¥3.06 Billion | +17.02% |
| 1998-12-31 | CN¥2.61 Billion | +340.68% |
| 1997-12-31 | CN¥592.54 Million | +18.02% |
| 1996-12-31 | CN¥502.07 Million | +11.61% |
| 1995-12-31 | CN¥449.83 Million | +6.66% |
| 1994-12-31 | CN¥421.76 Million | -- |
About Shanghai Pharmaceuticals Holding Co Ltd
Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemical and biological drugs, Chinese medicine, health care products, and medical devices to treat immunology, psychiatric … Read more